JD had a great post on this last August about some of the considerations facing Bioasis for Phase 0 and Phase 1 trials. A Phase 0 trial should be relatively quick, since it is a small dose for a short time in a small number of patients. If it is a Phase 0 trial, such as is rumored for the Herceptin/Trastuzumab program (Mtfp-TZM), the trial should be relatively cheap and quick compared to a Phase 1. As for the LSD program, I am not sure if they'd be starting at Phase 0 or Phase 1 there....but the same considerations that JD brought up for Mtfp-TZM apply to the Mtfp-LSD program. Phase 1 would be much more expensive, take longer, require more compound and require more patients than a Phase 0. Without more detail from the company, it is hard to project costs/timelines.

BearDownAZ